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Abstract
Background: Tuberculosis (TB) is the highest-mortality infectious disease in the world and the main cause of death related to
antimicrobial resistance, yet its surveillance is still paper-based. Rifampicin-resistant TB (RR-TB) is an urgent public health
crisis. The World Health Organization has, since 2010, endorsed a series of rapid diagnostic tests (RDTs) that enable rapid
detection of drug-resistant strains and produce large volumes of data. In parallel, most high-burden countries have adopted
connectivity solutions that allow linking of diagnostics, real-time capture, and shared repository of these test results. However,
these connected diagnostics and readily available test results are not used to their full capacity, as we have yet to capitalize on
fully understanding the relationship between test results and specific rpoB mutations to elucidate its potential application to
real-time surveillance.
Objective: We aimed to validate and analyze RDT data in detail, and propose the potential use of connected diagnostics and
associated test results for real-time evaluation of RR-TB transmission.
Methods: We selected 107 RR-TB strains harboring 34 unique rpoB mutations, including 30 within the rifampicin
resistance–determining region (RRDR), from the Belgian Coordinated Collections of Microorganisms, Antwerp, Belgium. We
subjected these strains to Xpert MTB/RIF, GenoType MTBDRplus v2.0, and Genoscholar NTM + MDRTB II, the results of
which were validated against the strains’ available rpoB gene sequences. We determined the reproducibility of the results, analyzed
and visualized the probe reactions, and proposed these for potential use in evaluating transmission.
Results: The RDT probe reactions detected most RRDR mutations tested, although we found a few critical discrepancies between
observed results and manufacturers’ claims. Based on published frequencies of probe reactions and RRDR mutations, we found
specific probe reactions with high potential use in transmission studies: Xpert MTB/RIF probes A, Bdelayed, C, and Edelayed;
Genotype MTBDRplus v2.0 WT2, WT5, and WT6; and Genoscholar NTM + MDRTB II S1 and S3. Inspection of probe reactions
of disputed mutations may potentially resolve discordance between genotypic and phenotypic test results.
Conclusions: We propose a novel approach for potential real-time detection of RR-TB transmission through fully using digitally
linked TB diagnostics and shared repository of test results. To our knowledge, this is the first pragmatic and scalable work in
response to the consensus of world-renowned TB experts in 2016 on the potential of diagnostic connectivity to accelerate efforts
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to eliminate TB. This is evidenced by the ability of our proposed approach to facilitate comparison of probe reactions between
different RDTs used in the same setting. Integrating this proposed approach as a plug-in module to a connectivity platform will
increase usefulness of connected TB diagnostics for RR-TB outbreak detection through real-time investigation of suspected
RR-TB transmission cases based on epidemiologic linking.
(JMIR Med Inform 2018;6(1):e12)   doi:10.2196/medinform.9309
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Introduction
Tuberculosis (TB) has the highest mortality of any infectious
disease and is the principal cause of death related to
antimicrobial resistance [1]. Efforts to control TB are
continuously hampered by complex regimens and low treatment
success of drug-resistant cases [1,2]. Multidrug-resistant TB
(MDR-TB), defined as resistance to the first-line drugs
rifampicin and isoniazid, remains an urgent public health crisis,
as only about 39% of notified, confirmed, and previously treated
people with TB were tested for rifampicin resistance in 2016,
and only 1 in 5 received treatment, of whom only half were
cured [1].
Rifampicin resistance is an epidemiologically and clinically
important surrogate marker for MDR-TB, as most
rifampicin-resistant strains are also resistant to isoniazid [2-4].
Rifampicin resistance-conferring mutations are primarily situated
at codon positions 426 to 452 [2] within the 81-bp rifampicin
resistance–determining region (RRDR) of the Mycobacterium
tuberculosis RNA polymerase β subunit (rpoB) gene [4-6].
Consequently, commercially available molecular tests developed
for rapid detection of MDR-TB only capture mutations in the
RRDR, with or without mutations associated with isoniazid
resistance [2,3,6].
Recognizing the immediate need to rapidly detect
rifampicin-resistant TB (RR-TB), the World Health Organization
has recommended implementation of the following rapid
diagnostic tests (RDTs) as primary tools for detection: Xpert
MTB/RIF (Cepheid, Sunnyvale, CA, USA), GenoType
MTBDRplus v2.0 (Hain Lifescience GmbH, Nehren, Germany),
and Genoscholar NTM + MDRTB II (NIPRO Corporation,
Osaka, Japan). Xpert MTB/RIF is the most widely deployed
RDT globally, implemented as the initial diagnostic tool by 28
out of 48 high-burden countries for patients with pulmonary
TB symptoms by the end of 2016 [1]. It uses real-time
polymerase chain reaction and molecular beacon technology,
involving probes specifically binding to wild-type sequences,
whereas the other RDTs are line probe assays, which rely on
hybridization and comprise both wild-type and mutant probes.
The specific features and limitations of the RDTs, along with
key recommendations from the World Health Organization,
have been previously described [6]. The global integration and
scale-up of these RDTs in TB diagnostics has dramatically
improved detection of MDR-TB [1,4,6-8].
Large gaps in detection and treatment of RR-TB can result in
resistant strains circulating within populations [7,9]. Particularly
in high-burden settings, transmission was found to be the
predominant cause of the globally rising rates of RR-TB and
MDR-TB [8,10,11], with an estimated 600,000 new cases of
RR-TB arising in 2016, of which 490,000 were MDR-TB [1,8].
To achieve the global targets of ending TB by 2030 [1], there
is an urgent need to shift from the current inefficient paper-based
investigation of drug-resistant cases to fully digitized
surveillance allowing for real-time detection of transmission
hotspots.
When Xpert MTB/RIF was rolled out in 2010, there was no
system in place to systematically extract, interpret, and employ
test results for surveillance. Accumulating data stored in local
machines were clearly underused; portions of data even get
corrupted and are not used at all. For a few years after, the gap
in TB diagnostics implementation was addressed by the
emergence of diagnostic eHealth solutions, particularly the
development of connectivity solutions. Xpert MTB/RIF
machines are now being linked, along with generated test results,
to connectivity platforms such as DataToCare (Savics, Brussels,
Belgium) and GxAlert (SystemOne, Springfield, MA, USA).
These connectivity platforms automate the collection of
diagnostic test results from each health facility in a particular
setting. They consolidate all data into a built-in analytics system
that automates extraction of useful information from raw test
data. Generated information is then securely shared with
different stakeholders—clinicians, national TB control programs,
and patients—through text messaging, email, or a national
database [12].
Despite this technological advancement, readily available and
accumulating TB diagnostic test results have not been used to
date for disease surveillance, due to the limited understanding
of the correlation between RDT probe reactions and specific
rpoB mutations. In accordance with the consensus of global TB
experts on the potential of diagnostic connectivity for TB
elimination published in 2016 [12], we believe that RDT results
coupled with appropriate analysis may present crucial clinical
and public health information that could be employed as a
molecular epidemiologic tool in field conditions to trace RR-TB
transmission hotspots in high-burden TB settings. They could
also aid in resolving the discordance between phenotypic drug
susceptibility testing and RDT results, primarily for disputed
mutations, which are often missed in Mycobacterium growth
indicator tube phenotypic drug susceptibility testing [13]. In
this work, we aimed to analyze RDT data in detail, visualize
test results representing specific RRDR mutations, and propose
a novel approach of fully using digitally linked TB diagnostics
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and readily available test results for real-time monitoring of
RR-TB transmission.
Methods
Source and Overview of Strains
We selected 107 RR-TB strains harboring 34 unique rpoB
mutations, including 30 within the RRDR (Multimedia Appendix
1), from the Belgian Coordinated Collections of Microorganisms
and the World Health Organization Tropical Disease Research
mycobacteria collection in the Institute of Tropical Medicine,
Antwerp, Belgium. We prepared thermolysates of these strains
as previously described, stored them at –20°C [14], and
subjected them to RDTs, namely Xpert MTB/RIF, GenoType
MTBDRplus v2.0, and Genoscholar NTM + MDRTB II.
Xpert MTB/RIF Assay G4 Version 5
We measured the DNA concentration of the thermolysates
through an Invitrogen Qubit 2.0 Fluorometer (Thermo Fisher
Scientific, Waltham, MA, USA) following the manufacturer’s
instructions. The calculated weight of DNA per M tuberculosis
bacillus served as the divisor for each DNA concentration, the
quotient of which was the equivalent colony-forming units
(CFUs) per milliliter of each thermolysate.
We subjected thermolysates with initial concentrations of 108
to 109CFU/mL to 1:2 and 10-fold serial dilutions until we
obtained 106 to 107CFU/mL, respectively. We then dispensed
a 1:2 mixture of diluted thermolysate and sample reagent in the
Xpert MTB/RIF cartridge following the manufacturer’s
instructions.
GenoType MTBDRplus v2.0 and Genoscholar NTM +
MDRTB II
We subjected undiluted thermolysates to the amplification and
hybridization steps of GenoType MTBDRplus v2.0 and
Genoscholar NTM + MDRTB II following the manufacturers’
instructions.
Analysis and Visualization of Rapid Diagnostic Test
Data
We validated RDT results against the strains’ rpoB gene
sequences, allowing for correlation between probe reactions
and specific rpoB mutations. We then performed a
comprehensive comparison and analysis of rpoB mutants and
associated RDT results using the consensus numbering system
based on M tuberculosis strain H37Rv [2]. We visualized results
of the analysis using Geneious version 10.1.2 (Biomatters
Limited) [15] and Affinity Designer 1.5.3 (Serif (Europe) Ltd)
[16]. The percentage average reproducibility of the RDTs was
analyzed through mutation profiles found in more than one
strain.
Results
All strains with mutations in the RRDR were correctly identified
as rifampicin resistant, except for one strain with the
S428R+H445R mutation that was not initially detected as M
tuberculosis by Xpert MTB/RIF but was confirmed as
rifampicin-resistant M tuberculosis on retesting; a strain with
the D435F mutation and another strain with the L430P mutation
were identified as rifampicin susceptible by GenoType
MTBDRplus v2.0 even after a repeat test. On the probe level,
each test appeared to be reproducible, ranging between 87.9%
and 97.8% (Multimedia Appendix 2). Among the RDTs,
Genoscholar NTM + MDRTB II yielded the highest concordance
between coverage claimed by manufacturers and that observed
experimentally.
The alignment of mutant and wild-type RRDR sequences in
Multimedia Appendix 1 shows the nucleotide and amino acid
change for each mutation profile captured by rpoB sequencing.
Multimedia Appendix 1 provides supporting information for
Figure 1, a visualization of the probe reactions demonstrating
the ability of the RDTs to capture the majority of documented
RRDR mutations.
Figure 1 was generated based on observed probe reactions for
each individual mutation. Hence, strains with double or triple
mutations were scored twice or thrice. For instance, from a
strain with the double mutation L430P+H445Q, the probe
reaction for L430P was deduced as Xpert MTB/RIF probe A,
GenoType MTBDRplus v2.0 probe WT2, and Genoscholar
NTM + MDRTB II probe S1, whereas the probe reaction for
H445Q was Xpert MTB/RIF probe D; for GenoType
MTBDRplus v2.0, was WT7; and for Genoscholar NTM +
MDRTB II, was S4. As expected, we found a strong correlation
between observed and claimed probe reactions of RRDR
mutations (Figure 1, black and green, represented by
low-prevalence mutations L430P, D435G, S441L or S441Q,
and L452P), although we noted delayed reactions in Xpert
MTB/RIF, denoting partial inhibition of fluorescence of a
particular molecular beacon [3], shown in green. It is interesting
to note that some mutations were missed by one probe but
captured by another, such as 435 mutations missed by Xpert
MTB/RIF probe C but captured by probe B, and a codon 437
mutation in the line probe assays (Figure 1, blue mutations).
End-probe mutations correctly identified by both probes in
GenoType MTBDRplus v2.0 were Q432E (WT2 and WT3) and
S441Q or S441L (WT5 and WT6). Critically, there were
individual mutations completely missed by the RDTs, namely
M434T and N437D by Xpert MTB/RIF, S428R and D435F by
GenoType MTBDRplus v2.0, and M4343V by Genoscholar
NTM + MDRTB II (Figure 1, red mutations). T444T is a silent
mutation appropriately undetected by GenoType MTBDRplus
v2.0, but it was captured by Xpert MTB/RIF and Genoscholar
NTM + MDRTB II.
We gathered the observed probe reactions representing each of
the 30 RRDR mutations tested (Figure 2).
For instance, Xpert MTB/RIF probe E, GenoType MTBDRplus
v2.0 probes WT8 and MUT3, and Genoscholar NTM + MDRTB
II probes S5 and R5 correspond with mutation S450L, with the
highest worldwide prevalence [17-19].
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Figure 1. Overview of rifampicin-resistant tuberculosis rapid diagnostic test (RDT) probe reactions. The observed results for each rifampicin
resistance–determining region mutation are overlaid on claimed probe coverage (light gray) of (A) Xpert MTB/RIF, (B) GenoType MTBDRplus v2.0,
and (C) Genoscholar NTM + MDRTB II. Mutations yielding the expected probe reactions are in black and green, with delayed XpertMTB/RIF results
in green, mutations missed by one probe but captured by another probe in blue, and mutations that were not at all captured by the RDT in red. Probe
reactions overlaid on each other are in a striped pattern for greater visibility.
Figure 2. Rapid diagnostic test (RDT) probe reactions corresponding with specific rifampicin resistance–determining region (RRDR) mutations. Probe
reactions with high potential use for transmission studies are bolded, while delayed probe reactions are tagged with superscript D shown in green.
Finally, we observed a possible association of delayed Xpert
MTB/RIF probe reactions with weaker fluorescence in
end-probe codons and specific nucleotide substitution types.
This was exemplified by guanine-to-thymine transversion in
disputed mutation D435Y resulting in 53.8% of delays
(average∆Ct8) for probe B and thymine-to-cytosine transition
in end-probe disputed mutation L452P resulting in 25% delayed
results (average∆Ct6) for probe E (Multimedia Appendices 3-8).
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Discussion
Principal Findings and Comparison With Prior Work
Our laboratory validation of rifampicin-resistant strains and
visualization of results revealed the specific relationship between
unique RDT probe reactions and the majority of documented
rpoB mutations. We also found RDT probe reactions
representing low-frequency mutations in particular settings that
have a high potential for use in evaluating transmission. We are
proposing a novel approach to the optimal use of readily
available diagnostic data through the shift to fully automated
and digitized surveillance for real-time detection of RR-TB
transmission hotspots.
To our knowledge, this work is the first pragmatic and scalable
response to the consensus of world-renowned TB experts,
published in 2016 [12], that diagnostic connectivity has the
potential to eliminate TB. This is evidenced by the ability of
our proposed approach to facilitate comparison of probe
reactions between different RDTs used in the same setting,
potentially linked to an open source software platform, by the
Connected Diagnostics Initiative [12], for instance. Our findings
affirm the important role of diagnostic connectivity platforms
in accelerating TB control efforts and highlight the importance
of fully understanding the relationship between TB diagnostic
test results and drug resistance-conferring mutations. Our
proposed approach will maximize the use of connected RDTs
and associated data shared in repositories through a plug-in
module that will automatically translate RDT results to useful
information for RR-TB outbreak investigations. This will
potentially aid laboratory personnel, clinicians, and national TB
control programs in closing detection gaps of RR-TB cases by
revealing abnormal figures or trends in particular settings, as
well as real-time probable horizontal transmission and
epidemiologic linkage between patients.
The comprehensive analysis of claimed and observed probe
reactions revealed the ability of the RDTs to detect documented
RRDR mutations. Most of the RRDR mutations analyzed
yielded the expected result, concordant with manufacturers’
claims. We observed the highest concordance between observed
and claimed probe coverage in Genoscholar NTM + MDRTB
II, exemplified, for instance, by probe S2 detecting mutation
N437D, which was missed by Xpert MTB/RIF probe C and
GenoType MTBDRplus v2.0 probe WT5 (Figure 2,Multimedia
Appendix 1, and Figure 1). Remarkably, the mutations missed
by one RDT probe but captured by another were situated in the
regions where the probes overlap. This affirms the role of
overlapping probes in improving the usefulness of RDTs for
RR-TB detection. Critically, mutations M434T missed by Xpert
MTB/RIF and M434V missed by Genoscholar NTM + MDRTB
II are not yet catalogued in the Tuberculosis Drug Resistance
Mutation Database, nor in RefSeq [20,21]; hence, their clinical
relevance is yet to be determined. Alarmingly, missed mutations,
including N437D (Xpert MTB/RIF), S428R, and D435F
(GenoType MTBDRplus v2.0), are known to confer rifampicin
resistance [22]. These undetected rifampicin
resistance-conferring mutations within the RRDR, together with
those outside the RRDR, most notably the I491F mutation [2],
may be untraceably circulated through chains of transmission,
as samples with these mutations alone will be falsely classified
as rifampicin susceptible, rendering treatment ineffective.
Additionally, the impact of silent mutations such as T444T must
be further assessed to ensure that recommended probes generate
results with high specificity for rifampicin resistance.
Accordingly, we suggest that manufacturers review and modify
claims of mutation coverage based on the findings of this work.
Additionally, for future versions of the line probe assays,
manufacturers might consider synthesizing mutation probes that
would also capture low-frequency mutations. These proposed
modifications would improve identification of underlying
mutations and thus increase the usefulness of linked RDTs for
detection of rifampicin resistance and for epidemiologic
surveillance.
We also gathered probe reactions representing low- to
high-prevalence RRDR mutations [4,12,13,18,19,22] in the
most comprehensive comparison of rpoB mutants and associated
RDT probe reactions to date and propose their potential
application for transmission studies. The use of RDT probe
reactions in defined geographic settings for evaluating
transmission is grounded in the need to easily deduce the
underlying RRDR mutation to identify genotype clustering in
time and space. When probe reactions between 2 strains
correspond, even between distinct RDTs, the prevalence of
probe reactions and associated RRDR mutations in a given
setting must be considered when assessing the probability of a
transmission event taking place. This probability will be
relatively higher for probe reactions representing low-frequency
mutations. This is explained by the principle that, in a normal
distribution, the probability of plotting a low-frequency mutation
in the tail region is low. Fitting it in the exact same location for
the second time has much lower probability. Hence, when
low-frequency probe reactions representing less-prevalent
mutations correspond between 2 strains, an epidemiologic link
might exist between the 2, and the occurrence of transmission
can possibly be suspected. For example, Xpert MTB/RIF probe
C, with the lowest frequency in Pakistan and Nigeria [20,21],
is a potentially valid marker of S441L/Q transmission. To
differentiate between the 2 mutations, RDT probe reactions
must be combined with complementary genotyping test results.
This proposed approach is evidenced by mutations L452P [23]
and D435G [18] detected in strains epidemiologically linked to
an extensively drug-resistant TB outbreak in KwaZulu-Natal,
South Africa. Accordingly, we assert that Xpert MTB/RIF
probes A, Bdelayed, C, and Edelayed; GenoType MTBDRplus
v2.0 probes WT2, WT5, and WT6; and Genoscholar NTM +
MDRTB II probes S1 and S3, which have a low frequency in
specific settings [20,21] and detect less-prevalent mutations
(emphasized in Figure 2), have a high potential for use in
transmission studies. On the contrary, the probability of
detecting a highly prevalent probe reaction in the distribution
is high, but fitting it into the exact same point the second time
would have lower probability. It would be unlikely that this is
a random event solely attributable to high-frequency mutations
being enriched by evolutionary convergence [24]. Therefore,
when this is observed, further investigation of suspected cases
of transmission is necessary. Particularly in settings of low
RR-TB incidence, probe reactions corresponding with highly
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prevalent mutations such as Xpert MTB/RIF probes E, D, and
B [20,21], if repeatedly obtained in the same health facility,
may be potentially useful for finding an epidemiologic link
between strains. The potential usefulness of RDT probe reactions
for transmission studies lies in accounting for the frequency of
probe reactions and RRDR mutations associated with RR-TB
prevalence in a specific geographic setting. Linking this novel
approach to a connectivity software can potentially bring about
real-time reporting of suspected RR-TB transmission cases,
which national TB control programs and public health officials
may then investigate and confirm or exclude based on
epidemiologic linking.
In addition to analyzing routine RDT data for evaluating
transmission in detail, we found that RDT probe reactions
corresponding with disputed mutations, supplemented with rpoB
gene sequences linked to connectivity software, may assist in
resolving discordance between phenotypic and genotypic
rifampicin susceptibility results. Our observed probe reactions
for disputed mutations were concordant between Xpert
MTB/RIF and GenoType MTBDRplus v2.0, and were consistent
with previous reports [13]. In contrast with discordant Xpert
MTB/RIF and Mycobacterium growth indicator tube results due
to the disputed mutation L430P [13,25], reliable probe reactions
between RDTs were observed in this work. Consequently,
detecting Xpert MTB/RIF probe A, GenoType MTBDRplus
v2.0 probe WT2, or Genoscholar NTM + MDRTB II probe S1
would suggest an L430P mutation, despite obtaining a
rifampicin-susceptible Mycobacterium growth indicator tube
result. For other cases, disputed mutation D435Y can be
distinguished from other variations at position 435, particularly
from D435V, by a higher proportion of delayed results for probe
B (Multimedia Appendix 3). Another delayed reaction observed
was for probe E, associated with the disputed mutation L452P.
Delayed results [3] for Xpert MTB/RIF probes B and E could
be attributed to a reduced intensity of fluorescence in the
end-probe codons. Alternatively, the specific nucleotide
substitution, associated with the average proportion of delayed
results and ∆Cts (Multimedia Appendix 3), may have caused
the delays. These inferred associations may aid in better
differentiation of Xpert MTB/RIF probe reactions that have a
high potential use for assessing transmission and resolving
discordance between phenotypic and genotypic drug
susceptibility results. On the contrary, disputed mutations H445L
and H445N associated with high in vitro resistance [26] could
not be distinguished from undisputed mutations in codon 445;
complementary rpoB sequences would be very beneficial in
this case. We strongly suggest that each specific mutation and
RDT result be assessed case-by-case for discordant results when
compared with phenotypic drug susceptibility testing and their
potential for transmission clustering studies.
Scope and Limitation
The limitation of the study was the lack of strains with RRDR
mutations outside labeled codon positions in Figure 1. However,
to our knowledge, the uncovered mutations have not yet been
encountered in clinical isolates and thus are likely to be
extremely rare. This work is not a field evaluation of the
potential of connected TB diagnostic data, but rather a pragmatic
laboratory validation and analysis of test results.
Conclusions
We propose a novel approach for potential real-time detection
of RR-TB transmission through fully using connected TB
diagnostics and a shared repository of test results. To our
knowledge, this is the first pragmatic and scalable work in
response to the consensus of world-renowned TB experts in
2016 on the potential of diagnostic connectivity to accelerate
efforts to eliminate TB [12]. This is evidenced by the ability of
our proposed approach to facilitate comparison of probe
reactions between different RDTs used in the same setting.
While less-prevalent RDT probe reactions corresponding with
low-frequency mutations would be most suitable for evaluating
transmission, combining this approach with complementary
genotyping tests such as membrane-based spoligotyping,
MIRU-VNTR, deep targeted sequencing, or whole genome
sequencing on cultured isolates [9] would increase the resolution
of the approach in identifying RR-TB transmission hotspots.
Supplementing RDT test results with spoligotyping data, for
instance, not only illustrates data pooling [12], but also enhances
the discriminatory power of this combined approach to confirm
suspected cases of TB transmission. This proposed prospective
approach, inspired by the SpoNC tool, which combined pncA
sequencing and spoligotyping data for detection of
pyrazinamide-resistant TB transmission clusters [9], will be
validated against conventional approaches through strains with
specific mutations and originating from documented clusters.
Integrating the combined approach as an additional module in
the connectivity platform will not only automate the analysis
of shared RDT results and its translation into crucial clinical
and public health information, but also allow more precise
real-time estimation of transmitted RR-TB proportions in a
population. Detection of RR-TB transmission hotspots would
initiate a timely outbreak response and appropriate investigation
of suspected transmission cases based on epidemiologic linking
that would prevent further spread of TB.
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Multimedia Appendix 1
Alignment of Mycobacterium tuberculosis strain H37Rv and rifampicin resistance–determining region mutant sequences showing
alternative nucleotides and amino acids for each mutation profile analyzed.
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Multimedia Appendix 2
Reproducibility of RDT probe profiles determined through mutation profiles found in multiple strains.
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Multimedia Appendix 3
Mutations (with wild-type and mutant nucleotide bases) that returned delayed result for Xpert MTB/RIF with corresponding
nucleotide substitution type, capturing probe, location of codon with respect to claimed probe coverage, Ct, ∆Ct, and average
∆Ct values, and percentage of delayed result considering all strains tested.
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Multimedia Appendix 4
Ct curve of mutation D435Y captured by probe B with single transversion substitution type, Ct value 27.9 and ∆Ct 6.
[PDF File (Adobe PDF File), 52KB - medinform_v6i1e12_app4.pdf ]
Multimedia Appendix 5
Ct curve of mutation D435F captured by probe B with double transversion substitution type, Ct value 38.1 and ∆Ct 16.8.
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Multimedia Appendix 6
Ct curve of mutation D435V captured by probe B with single transversion substitution type, Ct value 38.6 and ∆Ct 17.
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Multimedia Appendix 7
Ct curve of mutation H445R captured by probe D with single purine transition substitution type, Ct value 27.5 and ∆Ct 8.2.
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Multimedia Appendix 8
Ct curve of mutation L452P captured by probe E with single pyrimidine transition substitution type, Ct value 24.5 and ∆Ct 6.
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